Compare Five9 Inc (FIVN) vs Royalty Pharma plc Class A Ordinary Shares (RPRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Five9 Inc vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Five9 Inc trades at $36.22 (market cap $2.63B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.88 (market cap $25.27B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 9.6× Five9 Inc's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while Five9 Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Five9 Inc for 72 Days and Royalty Pharma plc Class A Ordinary Shares for 1 Days on average.
| FIVN | RPRX | |
|---|---|---|
Market Cap | $2.63B | $25.27B |
Volume | 1,864,393 | 3,671,183 |
Sector | Technology | Health |
52-Week High | $38.65 | $63.96 |
52-Week Low | $13.61 | $35.44 |
Typical Hold Time | 72 Days | 1 Days |
Enterprise Value | $2.78B | $32.50B |
Dividend Yield | — | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Five9 (FIVN) trades at $36.4, up 7.76% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. Revenue growth is accelerating, reaching $1.15B in 2025, while net income turned positive at $39.42M. The stock is near its 52-week high, supported by strong AI-driven subscription growth and leadership in the contact center-as-a-service market.
Outlook remains positive given robust AI revenue growth and raised guidance, but risks include high valuation multiples and insider selling. Analyst consensus is bullish with a $34 price target, though the current price exceeds it, suggesting near-term consolidation may occur before further upside.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Five9 Inc
Five9 provides cloud-native contact center software that enables digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement capabilities, and various software modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's artificial intelligence and automation portfolio supplements and enhances the firm's core CCaaS offerings, including solutions for digital self-service, agent assist technology, and workflow automation. Five9 also offers workforce optimization products that optimize call center efficiency through workforce management solutions, manage interaction quality, and track agent performance.
Read more on FIVN →About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →
